Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO GuidelineLarissa A. Korde, Dawn L. Hershman, Elizabeth A. Morris et al.|Journal of Clinical Oncology|2021Cited by 991
Current Landscape of Immunotherapy in Breast CancerSylvia Adams, Elizabeth A. Mittendorf, Margaret E. Gatti‐Mays et al.|JAMA Oncology|2019Cited by 409
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramFátima Cardoso, Sharon H. Giordano, John M.S. Bartlett et al.|Annals of Oncology|2017Cited by 396
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 TrialA. Jo Chien, Laura J. Esserman, Debasish Tripathy et al.|Journal of Clinical Oncology|2020Cited by 113